Old Web
English
Sign In
Acemap
>
authorDetail
>
M Salganik
M Salganik
Pfizer
Medicine
Psoriasis
Clinical endpoint
Placebo
Dermatology
2
Papers
39
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.
2018
British Journal of Dermatology
G.J. Schmieder
Z. D. Draelos
David M. Pariser
Christopher Banfield
L.A. Cox
Martin R. Hodge
Elizabeth Kieras
D. Parsons-Rich
Sandeep Menon
M Salganik
Karen Page
E. Peeva
Show All
Source
Cite
Save
Citations (37)
A novel flow cytometric-based method to measure kinase inhibition in sputum from COPD subjects.
2016
BMJ Open Respiratory Research
Grant C. Nicholson
Rebecca Holloway
B. R. Leaker
Iain Kilty
M Salganik
Lisa Tan
Peter J. Barnes
Louise E. Donnelly
Show All
Source
Cite
Save
Citations (2)
1